by Simran Chahal | Oct 9, 2012 | Health, News
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex’s rheumatoid arthritis (RA) 14-3-3η...
by Simran Chahal | Sep 6, 2012 | Health, News
When early discoveries are made at universities, they usually require additional research and funding to uncover what the innovation’s clinical usefulness will be to patients and physicians. For example, in 2006 researchers at the University of British Columbia...
by Simran Chahal | Jun 15, 2012 | Health, News
At Europe’s premier arthritis congress, the European League Against Rheumatism (EULAR) last week in Berlin, researchers presented findings that a protein measurable in blood named 14-3-3η, marks the presence of joint damage in two different forms of arthritis,...
by Simran Chahal | Nov 18, 2011 | Health, News
Not unlike cancer, disease outcome can be dramatically improved if RA is caught and treated early. Augurex Life Sciences Corp. reported that in Chicago at the American College of Rheumatology (ACR) Annual Scientific Meeting, world-leading arthritis researchers from...
by Simran Chahal | May 28, 2011 | Health, News
Company’s novel biomarker and drug target could represent the first personalized medicine in RA promise for future targeted therapy in a multi-factorial disease. Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism...
